This article is more than 5 years old. Information may no longer be current.

Top stories in hematology and oncology: FDA approves Kymriah, grants priority review to Keytruda

Among the top stories in hematology and oncology is tisagenlecleucel receiving FDA approval for expanding indications to include treatment of patients with relapsed or refractory large B-cell lymphoma. The FDA also granted priority review to a supplemental biologics license application that seeks approval of pembrolizumab to be used with pemetrexed and platinum chemotherapy. Other stories include an analysis of what patients treated with chimeric antigen receptor T-cell therapy actually pay, a blood test developed at John Hopkins Kimmel Cancer Center designed to screen for eight most common cancer types, and a report that only two-thirds of American aged 50 to 75 are up to date with colorectal cancer screening.

FDA expands approval of Kymriah to include relapsed or refractory large B-cell lymphoma

The FDA expanded the approval of tisagenlecleucel to include treatment of patients with relapsed or refractory large B-cell lymphoma, according to the agent’s manufacturer. Read More.

FDA grants priority review to Keytruda as part of non-small cell lung cancer regimen

The FDA granted priority review to a supplemental biologics license application that seeks approval of pembrolizumab for use in combination with pemetrexed and platinum chemotherapy for the treatment of patients with newly diagnosed metastatic nonsquamous non-small cell lung cancer. Read More.

Analysis determines true cost for CAR T-cell therapy

Patients treated with chimeric antigen receptor T-cell therapy will incur on average $30,000 to $36,000 in additional costs aside from drug expenses, according to a research letter published in JAMA Oncology. Read More.

Novel blood test aims to detect cancer in its earliest stages

Johns Hopkins Kimmel Cancer Center researchers have developed a blood test designed to screen for the eight most common cancer types. Read More.

‘Strategic menu’ of noninvasive options needed to boost colorectal cancer screening rates

Only two-thirds of Americans aged 50 to 75 years are up to date with colorectal cancer screening. Read More.